United Therapeutics Corp - UTHR STOCK NEWS

United Therapeutics Corporation (Nasdaq: UTHR) announced preliminary results from the EXPEDITE study, which evaluates the efficacy of Remodulin induction in patients with pulmonary arterial hypertension (PAH). In this phase 4 study, 79% of participants achieved a total daily dose of 12 mg of Orenitram after an induction period. The study involved 36 patients, with 29 completing the trial, indicating a significant improvement in dosing efficiency over traditional methods. These findings suggest a potential shift in treatment protocols for PAH.

United Therapeutics Corporation (Nasdaq: UTHR) is set to release its third quarter 2022 financial results on November 2, 2022, before market opening. A public webcast will follow at 9:00 a.m. Eastern Time on the same day, accessible through the company's website. United Therapeutics, a public benefit corporation, focuses on developing innovative pharmaceutical therapies and expanding organ transplant availability. The announcement includes caution about forward-looking statements regarding future operations and potential risks involved.

United Therapeutics Corporation (NASDAQ: UTHR) announced data from the INCREASE and FREEDOM-EV open-label extension studies, showcasing long-term safety for Tyvaso and improved survival in pulmonary arterial hypertension (PAH) patients using Orenitram. Presentations will occur at the CHEST 2022 Annual Meeting, highlighting gaps in initial combination therapy strategies for PAH. Events include the CHEST Women & Pulmonary Luncheon and a symposium on PH-ILD. These findings aim to enhance treatment strategies and outcomes for patients suffering from pulmonary hypertension.

United Therapeutics Corporation (Nasdaq: UTHR) has announced the enrollment of the first patient in the phase 3 TETON 2 study, involving 396 adult patients with idiopathic pulmonary fibrosis (IPF). This 52-week registration study aims to assess the impact of Tyvaso on forced vital capacity (FVC), a key prognostic indicator for IPF. The TETON program further investigates the antifibrotic effects of inhaled treprostinil. IPF is characterized by progressive lung scarring, leading to severe respiratory complications.

United Therapeutics Corporation (NASDAQ: UTHR) released its third annual Corporate Responsibility Report, showcasing its commitment to environmental, social, and governance (ESG) priorities. Highlights include the company's inaugural public benefit report, which emphasizes efforts to develop novel therapies and technologies for organ transplant availability. The report aligns with frameworks like GRI, SASB, and TCFD, and links progress to UN Sustainable Development Goals. The company is recognized as the first publicly traded biotech organized as a public benefit corporation.

United Therapeutics (NASDAQ: UTHR) reported a favorable ruling from the U.S. District Court regarding the infringement of its patents related to treprostinil inhalation. The Court determined that Liquidia Technologies' Yutrepia would infringe the ’793 patent, and an injunction preventing FDA approval until May 14, 2027, is expected. However, the Court invalidated certain claims of the ’066 patent. United Therapeutics plans to evaluate options for appeal regarding the ’066 patent while they continue to defend their intellectual property.

United Therapeutics Corporation (NASDAQ: UTHR) announced it will present four posters and one oral presentation at the upcoming European Society of Cardiology Congress 2022 and European Respiratory Society International Congress 2022 in Barcelona, Spain, from August 26 to September 6, 2022. The presentations will focus on clinical studies for Tyvaso^® (treprostinil) Inhalation Solution and Orenitram^® (treprostinil) Extended-Release Tablets, including data on event-free survival from the INCREASE study for Tyvaso in pulmonary hypertension associated with interstitial lung disease.

United Therapeutics Corporation (Nasdaq: UTHR) reported a 5% year-over-year revenue increase in Q2 2022, totaling $466.9 million. Key growth drivers included a 31% rise in Tyvaso sales, alongside the approval and launch of Tyvaso DPI for pulmonary arterial hypertension. However, net income fell 33% to $116.0 million, and EPS decreased 34%. The company is focused on ongoing clinical trials, notably for Tyvaso in various conditions, with a goal of reaching 6,000 patients on Tyvaso by year-end.

United Therapeutics Corporation (NASDAQ: UTHR) announced it will release its second quarter 2022 financial results on August 3, 2022, prior to market opening. A public webcast will follow at 9:00 a.m. ET on the same day, accessible via their website. United Therapeutics operates as a public benefit corporation, focusing on innovative therapies for patients and organ transplant technologies while aiming for superior financial performance and environmentally sustainable practices. Forward-looking statements are included in the release, cautioning potential risks and uncertainties.